摘要
UDP-N-乙酰-D-氨基半乳糖:多肽N-乙酰半乳糖胺转移酶-6(pp-GalNAc-T6)是N-乙酰-D-半乳糖胺转移酶家族的一个成员。它催化N-乙酰-D-半乳糖胺的添加物到蛋白质,通常首要步骤在蛋白的O-糖基化。糖基化蛋白在体内细胞膜中起重要作用。这些往往是参与细胞粘附,细胞骨架调节和免疫识别。许多类型的癌症已显示pp- GalNAc-T6上调。异常糖基化的粘蛋白1(酶的底物)的形式,在临床应用为乳腺癌的生物标志物。有可能使用其他pp-GalNAc-T6催化反应的产品。因为这种蛋白质往往在非恶性组织呈低的水平,也有可能是pp-GalNAc-T6本身被作为生物标志物。pp-GalNAc-T6已被涉及到恶性转化和癌细胞的转移。因此,它有相当大的可能作为化疗的靶点。至目前为止,没有确定选择性的酶的抑制剂。然而,普通的酶家族抑制剂导致降低细胞表面的O-连接的糖基化和诱导培养细胞的凋亡。因此,pp-GalNAc-T6选择性抑制剂可能靶向癌细胞,并可以开发成为新的抗癌疗法。
关键词: UDP-半乳糖胺,UDP-N-乙酰-D-氨基半乳糖,多肽肽N-乙酰半乳糖胺转移酶-6,癌症,转移,生物标志物,GALNT6。
Current Cancer Drug Targets
Title:UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase- 6 (pp-GalNAc-T6): Role in Cancer and Prospects as a Drug Target
Volume: 17 Issue: 1
Author(s): Samantha Banford and David J. Timson
Affiliation:
关键词: UDP-半乳糖胺,UDP-N-乙酰-D-氨基半乳糖,多肽肽N-乙酰半乳糖胺转移酶-6,癌症,转移,生物标志物,GALNT6。
摘要: UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyl transferase-6 (pp-GalNAc-T6) is a member of the N-acetyl-D-galactosamine transferase family. It catalyzes the addition of N-acetyl-D-galactosamine to proteins, often the first step in O-glycosylation of proteins. Glycosylated proteins play important roles in vivo in the cell membrane. These are often involved in cell-cell adhesion, cytoskeleton regulation and immune recognition. pp-GalNAc-T6 has been shown to be upregulated in a number of types of cancer. Abnormally glycosylated forms of mucin 1 (a substrate of the enzyme), are used clinically as a biomarker for breast cancer. There is potential for other products of the pp-GalNAc- T6 catalyzed reaction to be used. It is also possible that pp-GalNAc-T6 itself could be used as a biomarker, since levels of this protein tend to be low in non-malignant tissues. pp- GalNAc-T6 has been implicated in malignant transformation and metastasis of cancer cells. As such, it has considerable potential as a target for chemotherapy. To date, no selective inhibitors of the enzyme have been identified. However, general inhibitors of the enzyme family result in reduced cell surface O-linked glycosylation and induce apoptosis in cultured cells. Thus, a selective inhibitor of pp-GalNAc-T6 is likely to target cancer cells and could be developed into a novel anticancer therapy.
Export Options
About this article
Cite this article as:
Samantha Banford and David J. Timson , UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase- 6 (pp-GalNAc-T6): Role in Cancer and Prospects as a Drug Target, Current Cancer Drug Targets 2017; 17 (1) . https://dx.doi.org/10.2174/1568009616666160922102641
DOI https://dx.doi.org/10.2174/1568009616666160922102641 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
Role of Immune and Genotoxic Response Biomarkers in Tumor Microenvironment in Cancer Diagnosis and Treatment
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process of exploring and investigating the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
The Impact of Cancer Neuroscience on Novel Brain Cancer Treatment
Brain cancer remains one of the most challenging malignancies due to its complexity and resistance to conventional therapies. Recent advancements in cancer neuroscience have transformed our understanding of the brain's tumor microenvironment, offering promising insights into novel treatments. By studying the intricate interactions between cancer cells and the nervous system, ...read more
Unraveling the Tumor Microenvironment and Potential Therapeutic Targets: Insights from Single-Cell Sequencing and Spatial Transcriptomics
This special issue will focus on unraveling the complexities of the tumor microenvironment (TME) and identifying key biomarkers for potential therapeutic targets using advanced multi-omics techniques, such as single-cell sequencing and spatial transcriptomics. We seek original research and comprehensive reviews that investigate the heterogeneity and dynamics of the TME, emphasizing ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Engineering “Antimicrobial Peptides” and Other Peptides to Modulate Protein-Protein Interactions in Cancer
Current Topics in Medicinal Chemistry Tamoxifen and its New Derivatives in Cancer Research
Recent Patents on Anti-Cancer Drug Discovery Genetics of Bladder Malignant Tumors in Childhood
Current Genomics Endometrial Adenofibroma in a Patient Receiving Toremifene: A Case Report
Current Medical Imaging Biocompatible Magnetic Hollow Silica Microspheres for Drug Delivery
Current Organic Chemistry From Test Tube to Clinical Trial; Promising Herbs with NF-κB and COX- 2 Activity
Current Immunology Reviews (Discontinued) Probiotic Lactobacilli: A New Perspective for the Treatment of Inflammatory Bowel Disease
Current Pharmaceutical Design PET and SPECT Radiotracers to Assess Function and Expression of ABC Transporters In Vivo
Current Drug Metabolism Chimeric Antigen Receptor T Cells: Self-Replicating Drugs for Cancer
Current Drug Targets A Combination of EGFR Inhibitors and AE-PDT Could Synergistically Suppress Breast Cancer Progression
Anti-Cancer Agents in Medicinal Chemistry Cannabinoids
Current Drug Targets - CNS & Neurological Disorders Multifaceted Role of Neuropilins in Cancer
Current Medicinal Chemistry Schiff Bases and Complexes: A Review on Anti-Cancer Activity
Anti-Cancer Agents in Medicinal Chemistry Inhibition of Protein Kinase c-Src as a Therapeutic Approach for Cancer and Bone Metastases
Anti-Cancer Agents in Medicinal Chemistry Molecular Mechanisms and Treatment of Radiation-Induced Lung Fibrosis
Current Drug Targets The Regulation of miRNAs in Inflammation-Related Carcinogenesis
Current Pharmaceutical Design The Potential of Secondary Metabolites from Plants as Drugs or Leads Against Protozoan Neglected Diseases – Part I
Current Medicinal Chemistry Immune Modulation by Regulatory T Cells in Helicobacter pylori-Associated Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Critical Questions for Preclinical Trials on Safety and Efficacy of Vascular Endothelial Growth Factor-Based Therapeutic Angiogenesis for Ischemic Stroke
CNS & Neurological Disorders - Drug Targets Pediatric Immune Dysfunction and Health Risks Following Early-Life Immune Insult
Current Pediatric Reviews